Immuneering (US:IMRX) Globenewswire·2025-12-23 13:00Core Insights - Immuneering Corporation is set to provide an update on the 12-month overall survival data from its ongoing Phase 2a clinical trial of atebimetinib combined with modified Gemcitabine/nab-paclitaxel (mGnP) for first-line pancreatic cancer patients on January 7, 2026 [1][2] Company Overview - Immuneering Corporation is a late-stage clinical oncology company focused on improving the lives of cancer patients through innovative treatments [3] - The company is developing a new category of cancer medicines known as Deep Cyclic Inhibitors, with its lead product candidate, atebimetinib, being an oral, once-daily treatment targeting MEK [3] - Atebimetinib is designed to enhance durability and tolerability across various cancer types, particularly MAPK pathway-driven tumors like pancreatic cancer [3] - A Phase 3 trial for atebimetinib in first-line pancreatic cancer is expected to begin dosing in mid-2026 [3]